Heparin-Induced Thrombocytopenia in a Nonthrombocytopenic Patient With Toxic Epidermal Necrolysis Causing Fatal Outcome: Is HIT Still a HIT?

被引:1
|
作者
Busche, Marc Nicolai [1 ]
Peters, Tina [1 ]
Knobloch, Karsten [1 ]
Vogt, Peter Maria [1 ]
Rennekampff, Hans-Oliver [1 ]
机构
[1] Hannover Med Sch, Dept Plast Hand & Reconstruct Surg, Burn Ctr, D-30625 Hannover, Germany
来源
JOURNAL OF BURN CARE & RESEARCH | 2009年 / 30卷 / 04期
关键词
MOLECULAR-WEIGHT HEPARIN; ARGATROBAN ANTICOAGULATION; UNFRACTIONATED HEPARIN; ANTIBODIES; THROMBOSIS; PLATELET-FACTOR-4; REPLACEMENT; THERAPY; RISK;
D O I
10.1097/BCR.0b013e3181ac05bf
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The definition of heparin-induced thrombocytopenia (HIT) has been modified over time; however, most definitions require a relative or absolute thrombocytopenia after exposure to heparin. Therefore, routine platelet count monitoring has been recommended for screening. We present the case of a 26-year-old male patient with toxic epidermal necrolysis who developed a rapid and fatal clinical presentation of HIT, without thrombocytopenia at the time of diagnosis. Because our patient did not present a relative or absolute thrombocytopenia at the time of serological and clinical confirmation of HIT, routine platelet count monitoring failed to detect HIT in our patient. As a result of the here presented case of rapid and fatal HIT, it may be prudent to consider if thrombocytopenia, although it is still a common and important hallmark of HIT, should be an absolute requirement for the definition of HIT. In cases of HIT without any thrombocytopenia, screening for HIT antibodies may be the only way to detect HIT early enough to react. Because there is a high incidence of HIT antibodies in the general population, which are not always associated with HIT, screening for HIT antibodies cannot be recommended for every patient receiving heparin. However, prospective studies may be useful in determining if routine screening for HIT antibodies can decrease the morbidity and mortality of HIT in critically ill patients receiving therapeutic doses of unfractionated heparin on the intensive care unit. (J Burn Care Res 2009;30: 747-751)
引用
收藏
页码:747 / 751
页数:5
相关论文
共 50 条
  • [41] Near fatal stent thrombosis in an aneurysmatic RCX as first manifestation of heparin induced thrombocytopenia (HIT) without thrombocytopenia
    Zoller, Marc
    Atmowihardjo, Iskandar
    Huch, Jeanette
    Albrecht, Ines
    Habedank, Dirk
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [42] Platelet factor 4/heparin-particle gel immunoassay (PaGIA) is a weak method for heparin-induced thrombocytopenia (HIT) evaluation of post cardio-pulmonary bypass surgery patients
    Ganzel, Chezi
    Rowe, Jacob
    Raveh, David
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 38 (03) : 314 - 320
  • [43] Successful Use of Danaparoid in Two Pregnant Women With Heart Valve Prosthesis and Heparin-Induced Thrombocytopenia Type II (HIT)
    Gerhardt, Andrea
    Scharf, Ruediger E.
    Zotz, Rainer B.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2009, 15 (04) : 461 - 464
  • [44] Increasing the Diagnostic Utility of Heparin-Induced Thrombocytopenia (HIT) Testing: An Academic Medical Center's Utilization Analysis and Intervention
    Parsons, Meredith G.
    Hobbs, Ryan A.
    Schmidt, Julie
    Merrill, Anna E.
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2025, 10 (01): : 26 - 35
  • [45] VLX-1005 Effectively Treats Heparin-induced Thrombocytopenia (HIT) Without Increasing The Risk For Bleeding
    Putzbach, Victoria
    Adili, Reheman
    Michael, James
    Maloney, David J.
    McKenzie, Steven E.
    Holinstat, Michael A.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2022, 42
  • [46] Optimization of laboratory diagnosis of heparin-induced thrombocytopenia using HemosIL-AcuStar-HIT-IgG assay
    Tucker, Catherine M.
    Rhoades, Ruben
    Sharma, Ruchika
    Gong, Jerald Z.
    LABORATORY MEDICINE, 2024, 55 (01) : 34 - 39
  • [47] Performance of 4T score and heparin–platelet factor 4 antibody in the diagnosis of heparin-induced thrombocytopenia (HIT) in cancer
    Myra Wong
    Thein Hlaing Oo
    Wei Qiao
    Naveen Garg
    Cristhiam M. Rojas-Hernandez
    Journal of Thrombosis and Thrombolysis, 2017, 44 : 261 - 266
  • [48] HEPARIN-INDUCED THROMBOCYTOPENIA AND FATAL THROMBOSIS IN A PATIENT WITH ACTIVATED PROTEIN-C RESISTANCE
    GARDYN, J
    SORKIN, P
    KLUGER, Y
    KABILI, S
    KLAUSNER, JM
    ZIVELIN, A
    ELDOR, A
    AMERICAN JOURNAL OF HEMATOLOGY, 1995, 50 (04) : 292 - 295
  • [49] Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT)
    Bakchoul, Tamam
    Giptner, Astrid
    Bein, Gregor
    Santoso, Sentot
    Sachs, Ulrich J. H.
    THROMBOSIS RESEARCH, 2011, 127 (04) : 345 - 348
  • [50] Thromboembolism prophylaxis as a cause of thromboembolic complications. An investigation into the incidence of heparin-induced thrombocytopenia (HIT) type II
    Ganzer, D
    Gutezeit, A
    Mayer, G
    Greinacher, A
    Eichler, P
    ZEITSCHRIFT FUR ORTHOPADIE UND IHRE GRENZGEBIETE, 1997, 135 (06): : 543 - 549